Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma is a phase 2 interventional study registered as NCT01843374 by MedImmune LLC, with 571 participants enrolled, started 2013-05-17 and due to reach its primary completion in 2016-01-24. Interventions recorded: Tremelimumab, Placebo. Conditions listed: Unresectable Pleural or Peritoneal Malignant Mesothelioma. No results are recorded here; the registry entry is the source.